What it's for (Indications)
- Ranolazine is clinically indicated for the treatment of chronic angina pectoris.
- It is approved to be used either as monotherapy or in combination with other antianginal therapies, such as beta-blockers, nitrates, or calcium channel blockers, for patients who have not achieved adequate symptomatic control with other agents, or who are intolerant to alternative treatments.
- It is important to note that ranolazine is not indicated for the acute treatment of angina episodes.
- Its therapeutic benefit is derived from its chronic administration, aimed at reducing the frequency of angina attacks and improving exercise tolerance in patients suffering from stable angina.
- The decision to initiate ranolazine therapy should be made after careful consideration of a patient's overall cardiovascular risk profile and existing medication regimen to ensure optimal patient outcomes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended starting dose for ranolazine is 500 mg administered orally twice daily. This initial dose can be titrated upwards to a maximum recommended dose of 1000 mg twice daily, based on the patient's symptomatic response and tolerability. Dosage adjustments should be carefully considered, particularly in patients with moderate hepatic impairment or in those concurrently taking moderate CYP3A inhibitors, where a maximum dose of 500 mg twice daily is recommended to mitigate the risk of increased plasma concentrations. Ranolazine tablets should be swallowed whole and not crushed, broken, or chewed to maintain their extended-release properties. The medication can be taken with or without food, providing flexibility in administration. It is crucial to monitor patients for adverse effects, especially QT interval prolongation, during dose titration and throughout treatment, to ensure optimal therapeutic benefit with acceptable safety profile. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects associated with ranolazine therapy include dizziness, headache, constipation, and nausea.
- These adverse events are typically mild to moderate in severity and often transient, frequently resolving with continued treatment or dose adjustment.
- Other frequently observed side effects may include asthenia, peripheral edema, abdominal pain, and dry mouth.
- More serious, albeit less common, adverse reactions warranting close monitoring include syncope, bradycardia, and hypotension, which may necessitate medical intervention.
- Of particular concern is the potential for dose-dependent QT interval prolongation, which, although rare, can theoretically increase the risk of Torsades de Pointes, a potentially life-threatening ventricular arrhythmia.
- Patients should be counseled on these potential side effects and advised to report any concerning symptoms to their healthcare provider promptly to facilitate appropriate management and ensure patient safety.
Serious Warnings
- Black Box Warning: Ranolazine (Ranola) does not carry an official FDA Black Box Warning. However, healthcare professionals must be acutely aware of several serious safety considerations that require diligent attention during patient management. These include the potential for dose-dependent QT interval prolongation, which, while rare, can predispose patients to ventricular arrhythmias, including Torsades de Pointes, especially in the presence of predisposing factors or concomitant use of other QT-prolonging medications. Significant drug interactions are a critical concern, particularly with strong and moderate inhibitors of CYP3A, which can substantially elevate ranolazine plasma levels, thus increasing the risk of adverse events, including QT prolongation. Ranolazine is also contraindicated in patients with severe hepatic impairment due to the risk of drug accumulation and toxicity. Careful patient selection, vigilant monitoring of electrocardiograms and potential drug interactions, and appropriate dose adjustments are paramount to ensure the safe and effective use of ranolazine in managing chronic angina pectoris and minimizing patient risks.
- Ranolazine can cause dose-dependent prolongation of the QT interval on the electrocardiogram, which may increase the risk of ventricular arrhythmias, including Torsades de Pointes.
- Although the absolute risk is considered low, caution is advised in patients with a history of QT prolongation, those with uncorrected hypokalemia or hypomagnesemia, or patients concomitantly taking other QT-prolonging medications.
- Renal impairment requires careful consideration; ranolazine is not recommended for patients with severe renal impairment (creatinine clearance < 30 mL/min) due to increased exposure, and dose reduction is advised for moderate impairment.
- Similarly, ranolazine is contraindicated in severe hepatic impairment (Child-Pugh Class C) and a maximum dose of 500 mg twice daily is recommended for moderate hepatic impairment due to impaired drug metabolism.
- Significant drug interactions can occur, particularly with strong and moderate CYP3A inhibitors, which can substantially increase ranolazine plasma concentrations, thereby exacerbating the risk of adverse effects, including QT prolongation.
- Patients should be thoroughly evaluated for potential drug interactions prior to and during ranolazine therapy to prevent serious adverse events.
How it Works (Mechanism of Action)
Ranolazine exerts its antianginal effects primarily through the selective inhibition of the late inward sodium current (I_Na) in cardiac myocytes. By reducing this persistent sodium influx during ventricular repolarization, ranolazine helps to mitigate intracellular sodium accumulation. This, in turn, lessens the activity of the sodium-calcium exchanger, leading to a decrease in intracellular calcium overload within the myocardial cells. The reduction in intracellular calcium overload improves diastolic relaxation, reduces myocardial wall tension, and subsequently lowers myocardial oxygen demand, thereby alleviating anginal symptoms and improving exercise tolerance. Unlike many other antianginal agents, ranolazine typically does not significantly affect heart rate or blood pressure, making it a valuable option for patients where such hemodynamic changes are undesirable or contraindicated. It also has minor inhibitory effects on other ion channels, including the hERG potassium channel, contributing to its potential for QT prolongation.